🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

Recruitingn/aAges 18 Years - anyAllIstanbul Saglik Bilimleri University
NCT07858864 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older * Diagnosis of obesity (BMI \>30 kg/m²) * Currently using a GLP-1 RA * No hearing, speech or cognitive impairment * Not receiving treatment for major depressive disorder and not using antidepressants * Verbal consent to participate Exclusion Criteria: * Diagnosis of diabetes * History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy * Pregnancy or breastfeeding * Walking impairment * Not meeting inclusion criteria or unwilling to participate
💊

What it tests

  • GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.
📍

Where

1 site
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy